Julia Bonavitacola

A depression prevention program was found to have differing levels of efficacy across youth participants who identified as White and Black living in the US. The study, published in the Journal of Consulting and Clinical Psychology,1 indicated that future research […]

An article from Forbes referenced a study published in the July 2022 issue of The American Journal of Managed Care® (AJMC®). The study, “Projected US Savings From Biosimilars, 2021-2025,” projected that biosimilars would save $38.4 million vs conditions from 2021

The Trump administration announced on Wednesday that it would extend the emergency declaration linked to the opioid overdose crisis that was originally set to expire on March 21, indicating the administration’s continued approach to treating the opioid crisis as a

The Trump administration is reportedly considering eliminating the HIV prevention division that is a part of the CDC in another move that targets government spending and HIV care.1 Although there is a possibility that this move could be made by

Annie Antar, MD, PhD, Johns Hopkins Medicine, discussed how those diagnosed with HIV can have different presentations of long COVID and how that needs to be considered when treating the long-term condition. Transcript What additional factors influence treatment decisions in

Michelle Hessen, OD, assistant professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins Medicine, spoke about the future direction of study when focusing on cyclosporine ophthalmic solution 0.09% (Cequa; Sun Pharmaceutical) and how it can help those with

Annie Antar, MD, PhD, Johns Hopkins Medicine, spoke about how the likelihood of long COVID symptoms was increased in patients living with HIV. Transcript How does long COVID affect health outcomes in patients with HIV compared with those without? One

The Conference on Retroviruses and Opportunistic Infections (CROI), held from March 9 to 12, 2025, in San Francisco, California, featured discussions on new treatments and breaking research, as well as ongoing developments in both COVID-19 and HIV. The conference opened

The American Journal of Managed Care has been informed that this previous study held several inaccuracies regarding topical cyclosporine, including calculation errors that could have affected the study’s conclusions. At the request of the authors, we are temporarily retracting the

Patients with HIV who were virally suppressed when using the combination therapy of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) (Biktarvy; Gilead Sciences) or oral antiretroviral therapy (ART) had noninferior results when switching to the single-tablet, daily dose of doravirine/islatravir (100/0.25 mg) (Merck), according